Healthcare Business

Huge PowerShares ETF Rebalance Means Massive Buying for 4 Biotech Stocks

Exelixis

Exelixis Inc. (NASDAQ: EXEL) is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on cabozantinib, its wholly owned inhibitor of multiple receptor tyrosine kinases. Positive results were recently announced for a Phase 3 pivotal trial of cabozantinib in patients with advanced renal cell carcinoma. The company recently announced FDA approval for a drug that can help delay the progression of advanced melanoma.

The Cowen team expects a block of 2,184,200 shares will be purchased on the close Tuesday, which represents a 61% increase over the 10-day average volume.

The consensus price target for Exelixis is $6. The stock closed Monday at $5.72.

MannKind

MannKind Corp. (NASDAQ: MNKD) focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes, and Cowen thinks it will see a massive buy of 2,405,300 shares of stock. That represents 41% of the 10-day average trading volume.

The company has been an incredibly volatile stock over the past few years. MannKind has launched its inhalable insulin product, which was on the burner seemingly forever.

The consensus price target is set at $4.67. MannKind shares closed trading on Monday at $2.

ALSO READ: 4 Deutsche Bank Top Pick Energy Stocks to Buy on Big Oil Pullback

We like to remind our readers that these transactions are hardly a well-kept secret, and many managers that shadow the ETFs are already putting on trades in front of the action. However, if you are looking to buy or sell these companies, the added liquidity on the close could be helpful. Investors should note that these are all very high-risk stocks that are only appropriate for aggressive trading accounts.

Sponsored: Tips for Investing

A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.

Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.